Skip to content
DataLookout
Menu

NCT06644443

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

StatusUnknown
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

TEAEs
Timeframe: From date of initial treatment to the 30 days after treatment

Secondary (1)

Disease-related clinical responses

Arms and interventions

Experimental:Treatment groupExperimental

patients treated with BCMA-GPRC5D CAR-T cells

Biologicals: BCMA-GPRC5D CAR-T cells

Sites

1 site in 1 country

  • Shenzhen University General HospitalShenzhen, Guangdong, China